1
Filed pursuant to Rule 424(b)(3)
Registration No. 333-10945
PROSPECTUS
U.S. ALCOHOL TESTING OF AMERICA, INC.
2,000,000 SHARES OF USAT COMMON STOCK ISSUABLE UPON
EXERCISE OF WARRANTS AND 9,757,775 SHARES
OFFERED BY SELLING STOCKHOLDERS
------------------------
U.S. Alcohol Testing of America, Inc. ("USAT"), is offering, by this
Prospectus, an aggregate of 2,000,000 shares of its Common Stock, $.01 par value
(the "USAT Common Stock"), issuable upon the exercise of USAT Common Stock
purchase warrants expiring December 17, 1999 (the "December 17 Warrants"). USAT
will receive gross proceeds of $4,000,000 if all of the December 17 Warrants are
exercised.
In addition, the stockholders named in the table under the caption "Selling
Stockholders" are offering, by this Prospectus, (1) an aggregate of 3,665,174
shares of the USAT Common Stock, all of which are currently outstanding,
consisting of (a) an aggregate of 2,000,000 shares which were issued in a
private placement by USAT, the final closing of which was held on February 14,
1996; (b) an aggregate of 500,000 shares of the USAT Common Stock issued in an
acquisition on May 21, 1996; and (c) an aggregate of 1,165,174 shares of the
USAT Common Stock previously issued upon the exercise of USAT Common Stock
purchase warrants and a stock option; (2) an aggregate of 437,500 shares
issuable upon the exercise of stock options (the "Options") expiring 30 days
from the date hereof; and (3) an aggregate of 5,655,101 shares of the USAT
Common Stock issuable upon the exercise of USAT Common Stock purchase warrants
expiring between October 31, 1996 and July 18, 2003. The Selling Stockholders
have advised USAT that they may, from time to time, offer the foregoing
9,757,775 shares at the prices then prevailing on the American Stock Exchange or
in isolated transactions, at negotiated prices, with institutional or other
investors. USAT will not receive any of the proceeds from the sales of the
shares of the USAT Common Stock by the Selling Stockholders. The following
executive officers and directors of USAT are among the Selling Stockholders:
Robert Stutman, Linda H. Masterson, Alan I. Goldman, John C. Lawn, Peter M. Mark
and Lee S. Rosen.
Since January 2, 1992, the USAT Common Stock has been listed and trades on
the American Stock Exchange under the symbol "AAA." The closing price of the
USAT Common Stock reported by such Exchange on September 16, 1996 was $2.4375.
------------------------
THE SHARES OFFERED BY THIS PROSPECTUS ARE SPECULATIVE IN THAT THEY INVOLVE
CERTAIN RISKS. SEE "RISK FACTORS" COMMENCING ON PAGE 6 HEREOF FOR A DISCUSSION
OF MATTERS WHICH SHOULD BE CONSIDERED BY PURCHASERS OF THESE SHARES.
- -----------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------
UNDERWRITING
DISCOUNTS PROCEEDS TO
PRICE TO PUBLIC AND COMMISSIONS(4) PROCEEDS TO ISSUER OTHER PERSONS
- -----------------------------------------------------------------------------------------------------------
Per share of Common Stock...... $ 2.4375(1) 0 0 $ 2.4375(1)
- -----------------------------------------------------------------------------------------------------------
Per Warrant share.............. $ 2.49(2) 0 $ 2.49(2) 0
- -----------------------------------------------------------------------------------------------------------
Per Option share............... $ 2.375(3) 0 $ 2.375(3) 0
- -----------------------------------------------------------------------------------------------------------
Total for Common Stock......... $23,705,358(1) 0 0 $23,705,358(1)
- -----------------------------------------------------------------------------------------------------------
Total for Warrant shares....... $19,024,052(2) 0 $19,024,052(2) 0
- -----------------------------------------------------------------------------------------------------------
Total for Option shares........ $ 1,039,863(3) 0 $ 1,039,863(3) 0
- -----------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------
(1) Based on the closing sales price of the USAT Common Stock on September 16,
1996 as reported by the American Stock Exchange.
(2) Based on the weighted average of the exercise prices of the USAT Common
Stock purchase warrants.
(3) Based on the exercise price of the Options.
(4) Excludes expenses estimated at $50,000.
------------------------
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES
AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION NOR HAS THE
COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR
ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL
OFFENSE.
The date of this Prospectus is October 4, 1996.
2
AVAILABLE INFORMATION
USAT is subject to the information requirements of the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), and, in accordance therewith,
files reports, proxy and information statements and other information with the
Securities and Exchange Commission (the "Commission"). Such reports, proxy and
information statements and other information filed by USAT can be inspected and
copied at the public reference facilities maintained by the Commission at 450
Fifth Street, N.W., Room 1024, Washington, D.C. 20549, as well at the following
regional offices of the Commission: 7 World Trade Center, Suite 1300, New York,
New York 10048 and Northwestern Atrium Center, 500 West Madison Street, Suite
1400, Chicago, Illinois 60661-2511. Copies of this material can also be obtained
at prescribed rates from the Public Reference Section of the Commission at its
principal office at 450 Fifth Street, N.W., Washington, D.C., 20549. The
Commission maintains a Web site that contains reports, proxy and information
statements and other information regarding registrants that file electronically
with the Commission at the following Web site address: http://www.sec.gov.
Because the USAT Common Stock is traded on the American Stock Exchange, reports,
proxy and information statements and other information concerning USAT can also
be inspected by contacting the American Stock Exchange, Inc., 86 Trinity Place,
New York, NY 10006-1881.
USAT has filed under the Securities Act of 1993, as amended (the
"Securities Act"), a Registration Statement on Form S-3, File No. 333-10945 (the
"Registration Statement"), pursuant to which (1) USAT will offer an aggregate of
2,000,000 shares of the USAT Common Stock issuable upon the exercise of the
December 17 Warrants and (2) certain of the Selling Stockholders named in this
Prospectus will offer an aggregate of 4,145,000 shares of the USAT Common Stock
issuable when and if the following USAT Common Stock purchase warrants (such
USAT Common Stock purchase warrants, together with the December 17 Warrants,
being collectively referred to herein as the "New Warrants") are exercised: (a)
an aggregate of 60,000 shares issuable upon the exercise of New Warrants
expiring November 15, 1998 (the "November 15 Warrants") issued to USAT directors
and a consultant; (b) an aggregate of 700,000 shares issuable to an USAT
director for his services upon the exercise of (i) a New Warrant expiring
November 15, 1998 as to 400,000 shares, (ii) a New Warrant expiring November 15,
2000 as to 150,000 shares and (iii) a New Warrant also expiring November 15,
2000 as to 150,000 shares (such three New Warrants being collectively referred
to herein as the "Director's Services Warrants"); (c) 300,000 shares issuable to
the same director for his services in connection with securing the exercises of
USAT Common Stock purchase warrants upon the exercise of a New Warrant expiring
April 17, 1999 (the "Director's Second Services Warrant"); (d) an aggregate of
235,000 shares issuable to employees of USAT or a subsidiary thereof upon the
exercise of New Warrants expiring between August 27, 1998 and July 18, 2003 (the
"Employee Warrants"); (e) an aggregate of 200,000 shares issuable to two persons
who are now employees of USAT (one of whom is now the Chairman of the Board and
Chief Executive Officer), but were originally issued to the person who is now
such officer for his consulting services, upon the exercise of New Warrants
expiring December 13, 1998 (the "December 13 Warrants"); (f) an aggregate of
200,000 shares issuable to the former shareholders of Robert Stutman Associates,
Inc. ("RSA") upon the exercise of New Warrants expiring March 31, 1999 (the
"March 31 Warrants"), which warrant (the "RSA Consulting Warrant") was
originally issued to RSA for its consulting services; (g) an aggregate of
900,000 shares issuable to the former RSA shareholders upon the exercise of New
Warrants expiring May 20, 1999 (the "May 20 Warrants"), which May 20 Warrants
were issued by USAT as part of the consideration for its purchase of RSA; (h)
600,000 shares issuable to the President and Chief Operating Officer of USAT
upon the exercise of a New Warrant expiring May 12, 1999 (the "May 12 Warrant");
(i) 150,000 shares issuable to a person in settlement of litigation upon the
exercise of a New Warrant expiring January 29, 2000 (the "January 29 Warrant");
(j) an aggregate of 100,000 shares issuable to two broker-dealers as a placement
fee for a Regulation S offering upon the exercise of New Warrants expiring
October 19, 2000 (the "October 19 Warrants"); and (k) 700,000 shares issuable to
a consultant for his financial public relations services upon the exercise of a
New Warrant expiring February 26, 1999 (the "February 26 Warrant"). USAT has
also filed Post-Effective Amendment No. 1 to Registration Statement on Form S-1,
File No. 33-90034 (the "January 1996 Registration Statement"), pursuant to which
certain of the Selling Stockholders named in this Prospectus will offer an
aggregate of 551,750 shares of the USAT Common Stock consisting of (1) an
aggregate of 77,500 shares of the USAT Common Stock issuable upon the exercise
of outstanding USAT Common Stock purchase warrants expiring on dates ranging
between
2
3
September 1, 1996 and December 31, 2001 (the "January 1996 Warrants"), (2) an
aggregate of 437,500 shares of the USAT Common Stock issuable upon the exercise
of outstanding options initially expiring August 1, 2004 (the "Options") granted
under USAT's 1990 Restricted Stock, Non-Qualified and Incentive Stock Option
Plan (the "1990 Option Plan"), (3) an aggregate of 24,250 shares of the USAT
Common Stock received upon the prior exercises of the January 1996 Warrants and
(4) 12,500 shares of the USAT Common Stock received upon the prior exercise of
an Option pursuant to the 1990 Option Plan. USAT has also filed Post-Effective
Amendment No. 4 to Registration Statement on Form S-1, File No. 33-43337 (the
"January 1992 Registration Statement"), pursuant to which certain of the Selling
Stockholders named in this Prospectus will offer an aggregate of 1,213,205
shares of the USAT Common Stock consisting of (1) an aggregate of 500,000 shares
of the USAT Common Stock registered as part of the Acquisition Shares and issued
to the former RSA shareholders and (2) an aggregate of 713,205 shares of the
USAT Common Stock received upon the prior exercises of USAT Common Stock
purchase warrants which expired September 1 or September 16, 1996 (the "January
1992 Warrants"). USAT has also filed Post Effective Amendment No. 3 to
Registration Statement on Form S-1, File No. 33-47855 (the "September 1992
Registration Statement"), pursuant to which the Selling Stockholders named in
this Prospectus will offer an aggregate of 1,772,070 shares of the USAT Common
Stock consisting of (1) an aggregate of 1,371,351 shares of the USAT Common
Stock to be issued upon the exercise of USAT Common Stock purchase warrants
expiring between October 31, 1996 and December 31, 1997 (the "September 1992
Warrants") and (2) an aggregate of 400,719 shares of the USAT Common Stock
received upon the prior exercises of the September 1992 Warrants. USAT has also
filed Post-Effective Amendment No. 2 to Registration Statement on Form S-1, File
No. 33-72680 (the "May 1994 Registration Statement"), pursuant to which certain
of the Selling Stockholders named in this Prospectus will offer an aggregate of
75,750 shares of the USAT Common Stock consisting of (1) an aggregate of 61,250
shares to be issued upon the exercise of USAT Common Stock purchase warrants
expiring between May 17, 1997 and September 1, 1998 (the "May 1994 Warrants")
and (2) an aggregate of 14,500 shares of the USAT Common Stock received upon the
prior exercises of the May 1994 Warrants. The New Warrants, the January 1996
Warrants, the January 1992 Warrants, the September 1992 Warrants and the May
1994 Warrants are collectively referred to herein as the "Warrants". The January
1992 Registration Statement also relates to an aggregate of 1,532,679 additional
shares of the USAT Common Stock to be offered by USAT to effect future
acquisitions and an aggregate of 977,321 additional shares already issued to
effect acquisitions, but such shares of the Acquisition Shares are not being
offered by this Prospectus.
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
The Company hereby incorporates by reference in this Prospectus the
following reports and registration statements of the Company filed pursuant to
Sections 12 and 13 of the Exchange Act:
1.(a) Annual Report on Form 10-K for the fiscal year ended March 31, 1996;
(b) Form 10-K/A amending the foregoing filed on September 23, 1996;
2.(a) Quarterly Report on Form 10-Q for the quarter ended June 30, 1996;
(b) Form 10-Q/A amending the foregoing filed on September 20, 1996;
3.(a) Current Report on Form 8-K filed on June 5, 1996;
(b) Current Report on Form 8-K/A filed on August 5, 1996;
(c) Current Report on Form 8-K/A filed on August 27, 1996;
(d) Current Report on Form 8-K/A filed on September 23, 1996;
4. Notice of Annual Meeting of Stockholders and Proxy Statement dated
September 12, 1996; and
5. Registration Statement on Form 8-A, File No. 0-18938.
3
4
All reports and definitive proxy or information statements filed pursuant
to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date
of this Prospectus and prior to the termination of the offering of the
securities shall be deemed to be incorporated by reference into this Prospectus
and to be a part hereof from the date of filing of such documents. Any statement
contained in a document incorporated or deemed to be incorporated by reference
herein shall be deemed to be modified or superseded for purposes of this
Prospectus to the extent that a statement contained herein or in any other
subsequently filed document which also is incorporated or deemed to be
incorporated by reference herein modifies or supersedes such statement. Any such
statement so modified or superseded shall not be deemed, except as so modified
or superseded, to constitute a part of this Prospectus.
Any person receiving a copy of this Prospectus may obtain without charge,
upon written or oral request of such person, any of the documents incorporated
by reference herein, except for the exhibits to such documents. Requests should
be directed to Robert Stutman, Chairman of Board and Chief Executive Officer,
U.S. Alcohol Testing of America, Inc., at the following address: 4517 North West
31st Avenue, Ft. Lauderdale, Florida 33309 or telephone number: (954) 739-9600.
A reasonable fee for duplicating and mailing will be charged for a copy of any
exhibit if such exhibit is requested.
THE COMPANY
U.S. Alcohol Testing of America, Inc. ("USAT") was incorporated on April
15, 1987 under the laws of Delaware to design, manufacture and market
instruments which measure blood alcohol concentration by breath sample and
analyzation. USAT maintains its principal executive offices at 10410 Trademark
Street, Rancho Cucamonga, California 91730, and its telephone number is (909)
466-8378.
USAT's subsidiaries operate in several different industries:
1. U.S. Drug Testing, Inc. ("U.S. Drug"), which is 67.0% owned by USAT and
whose common stock trades on the Pacific Coast Stock Exchange, is developing
proprietary systems that will test for drug use.
2. Good Ideas Enterprises, Inc. ("Good Ideas"), which is approximately
60.8% owned by USAT and whose common stock trades on the Pacific Coast Stock
Exchange, markets and distributes a variety of traditional toy products for
children of various ages.
3. ProActive Synergies, Inc. ("ProActive"), which is a wholly-owned
subsidiary of USAT incorporated in June 1995, provides single source services to
assist corporations in their hiring practices ranging from substance abuse
testing and background screening to total program management.
4. On May 21, 1996, USAT completed its acquisition of RSA, a provider of
corporate drug-free work place programs. Since January 1996, RSA has been
designing policies and programs on substance abuse prevention for customers of
the ProActive subsidiary.
5. Alconet, Inc. ("Alconet"), which is a wholly-owned subsidiary acquired
by USAT in March 1995, has developed an alcohol testing network to upload test
results and information from various alcohol breath testing devices.
U.S. Rubber Recycling, Inc. ("USRR"), which is a wholly-owned subsidiary of
USAT, manufactured and marketed floor covering products for office and
industrial use from used truck and bus tires. On April 30, 1996, USRR sold its
assets to an unaffiliated third party and discontinued operations.
USAT is also currently seeking to acquire the minority stock interests in
U.S. Drug by an offer of shares of the USAT Common Stock to the minority
stockholders of U.S. Drug as consideration for their consent to a merger (the
"U.S. Drug Merger") of U.S. Drug with and into Drug Testing Acquisition Corp., a
wholly-
4
5
owned subsidiary of USAT. There can be no assurance that the U.S. Drug Merger
will be successfully consummated.
USAT is also currently seeking to acquire the minority stock interests in
Good Ideas by an offer of shares of the USAT Common Stock to the minority
stockholders of Good Ideas as consideration for their consent to a merger (the
"Good Ideas Merger") of Good Ideas Acquisition Corp., a wholly-owned subsidiary
of USAT, with and into Good Ideas. Good Ideas was treated as a discontinued
operation in USAT's financial statements as of March 31, 1996. There can be no
assurance that the Good Ideas Merger will be consummated.
USAT and its subsidiaries will be collectively referred to herein as "the
Company."
5
6
RISK FACTORS
The shares offered hereby are speculative, involve a high degree of risk
and should not be purchased by anyone unable to afford a loss of his entire
investment. In analyzing this offering, prospective investors should consider
all of the matters set forth below.
1. Operating Losses. The Company has sustained losses of $42,858,501 from
inception through June 30, 1996. Management initiated cost reduction actions to
reduce selling, general and administrative expenses in the fiscal year ended
March 31, 1996 ("fiscal 1996"), which prospective savings were offset by the
$903,000 in combined legal and other expenses incurred by both parties in the
May to September 1995 consent solicitation contest, $250,000 in settlement of a
claim by two then Alconet officers relating to their then employment and
$397,000 of expenses incurred by Alconet, a subsidiary not included in the
fiscal year ended March 31, 1995 ("fiscal 1995"). Without the expenses of the
consent solicitation, management believes that the selling, general and
administrative expenses can be reduced in the fiscal year ending March 31, 1997
("fiscal 1997"); however, there can be no assurance that management's
expectations will be realized in fiscal 1997 or thereafter. In addition,
management has initiated an effort through ProActive, a subsidiary, to tap the
human resource provider market which it believes can result in substantial
revenues; acquired RSA on May 21, 1996, which company has been designing
drug-free workplace policies and programs for ProActive clients since January
1996; will continue to attempt to sell its toy operations; and has sold on April
30, 1996 the assets of its rubber recycling operations, so that the Company can
concentrate on alcohol and drug testing and the related RSA/ProActive operations
as its core businesses. However, there can be no assurance that management will
receive what it considers to be an acceptable offer for Good Ideas. In addition,
the Board will liquidate Good Ideas if no acceptable offer is received by
December 31, 1996. In addition, the decision to develop a saliva based drug
testing product, rather than complete first the urine based drug testing product
for marketing, will, in the opinion of management, enhance the Company's future
growth, but has delayed the receipt of any revenues from U.S. Drug for at least
one year later than fiscal 1997, if not longer, unless revenues are to be
received from a marketing and/or development partner if and when such an
agreement for such a partner is executed, as to which there can be no assurance,
especially because management is not conducting any negotiations for such a
partner. Accordingly, it is management's belief, especially in view of the
significant losses in the fiscal year ended March 31, 1994 ("fiscal 1994"),
fiscal 1995 and fiscal 1996, that, despite these management programs, the
Company will not turn profitable in fiscal 1997 and that, pending development of
the ProActive operations in conjunction with RSA, the timing of the U.S. Drug
development work and the other management programs, it is currently too
speculative to project as to when, if ever, the Company will become profitable.
2. Need for Financing. Because of the then projected continuing losses
from the Company's operations in fiscal 1996, USAT's management believed that it
was necessary to secure additional equity, through the private placement of its
securities, through the exercise of outstanding USAT Common Stock purchase
warrants or stock options or through a combination of both, in order to offset
the anticipated cash shortfall from operations. In November 1995, USAT
authorized a private placement pursuant to Regulation D under the Securities Act
offering 2,000,000 shares of the USAT Common Stock which resulted in $3,750,000
in gross proceeds upon the consummation of the offering on February 14, 1996.
Management believes that, as a result of this financing, the proceeds from the
sale of the assets of USRR, the recent and possible future exercises of the
outstanding Warrants and Options and the cash to be generated from its
operations, the Company will be able to meet its cash requirements during the
next 12 months. However, there can be no assurance that this objective will be
achieved and the Company in such event would have to seek new financing, which
financing may not be available or, if available, may not be on acceptable terms.
In addition, depending on market and other conditions relating to the individual
holder, there can be no assurance that the outstanding Warrants and Options will
be exercised and, if exercised, when. Since January 31, 1996 and through August
31, 1996, USAT Common Stock purchase warrants and stock options to purchase an
aggregate of 2,732,824 shares of the USAT Common Stock were exercised for an
aggregate exercise price of $4,754,088.
In the event that the Company is unable to generate sufficient cash flow
from operations or from sources other than operations as described in the
preceding paragraph (which event, in USAT's management's
6
7
opinion, is not likely to occur based upon the Company's past experience;
however, there can be no assurance that management will be successful in its
financing efforts), then the Company may have to reduce operations in order to
survive, thereby not only resulting in less cash from operations currently, but
also delaying future revenue growth. In such event the market price of the USAT
Common Stock is likely to drop, not only discouraging the future exercises of
USAT's Warrants and Options and possibly discouraging potential new investors,
but also increasing the risk that a current investor in USAT may lose the value
of his, her or its investment.
3. Competition. The Company has a variety of competitors depending on the
particular aspect of its business, many of which have far greater financial
resources and marketing staffs than the Company. There can be no assurance that
the Company will be able to compete successfully with these companies.
Alcohol Testing
The alcohol detection equipment industry is highly competitive. Although
management believes that USAT's Alco-Analyzer 2100 is the only Department of
Transportation approved evidential alcohol breath testing instrument utilizing
gas chromatography, it still competes with other alcohol detection techniques
developed by other companies. USAT competes with other small companies such as
CMI Inc., Intoximeters, Inc. and Lifeloc, Inc., which also offer alcohol testing
equipment. Although all of these competitors are believed currently to have
greater revenues than USAT from sales of alcohol testing devices, management is
of the opinion that only CMI, Inc., which is a subsidiary of MPD/MPH, may have
greater financial resources than USAT. In addition, several companies, including
Hoffman-LaRoche, Inc. ("Roche") and STC, Inc., offer an on-site screening saliva
based alcohol test. Roche has, and several of these other companies may have,
greater revenues and financial resources than the Company.
Drug Testing
The Company has not received any revenues from U.S. Drug because its
products are still in the developmental stage. Currently U.S. Drug is developing
two products which will screen for the presence of drugs of abuse, one which
will utilize flow immunosensor technology with urine samples as a medium of
testing and another which will utilize flow immunosensor technology with saliva
samples as a medium of testing. If the products are developed, U.S. Drug will
compete with many companies which currently utilize urine samples as a medium of
testing, such as Syva (a division of Syntex Corporation), Roche, Marion
Laboratories, Inc., Abbott Laboratories, Inc., Editek, Inc., Hycor Biomedical,
Inc., Princeton Bio Meditech, Inc. and Biosite, Inc., major pharmaceutical
companies which also provide substance abuse screening methods. Currently, to
management's knowledge, no competitor is offering a saliva based testing product
on an "on site" basis for drugs of abuse. However, management has been advised
that one or more companies may have such product under development and,
accordingly, there can be no assurance that a competitor will not offer such a
product in the future. Even if no such product is offered, U.S. Drug anticipates
competition from other substance abuse detection methods provided by the major
companies mentioned in this paragraph. If U.S. Drug successfully completes
development of first its saliva sample testing method and second its urine
sample testing method, as to which there can be no assurance, it is not certain
whether U.S. Drug will have the financial resources to compete successfully with
other companies which have greater financial resources available to them without
the assistance of a major pharmaceutical or other company possessing such
resources. There can be no assurance that the assistance of such a company can
be obtained, especially because none is currently being sought. In addition,
U.S. Drug's delay in bringing a drug testing product to market may adversely
affect its future marketing efforts because of the name recognition gained by
competitors actively marketing a product during this interim period.
Human Resource Provider Operations
ProActive is a single source service provider, meaning that it is a
provider of both substance abuse testing services and background screening
services. A single source service provider is a relatively new concept.
Additionally, the Company, through the acquisition in May 1996 of RSA, can also
provide customized loss prevention services specifically designed to reduce the
negative effect of workplace substance abuse. The
7
8
competition from single source providers which ProActive currently encounters is
primarily from small local and regional companies. To management's knowledge,
currently there is no single source provider on a national level, which is what
ProActive hopes to become, and there are no other providers of customized
programs and policies like RSA. However, Laboratory Corporation of America,
through Med-Express, is currently offering background screening services to
corporations on a limited basis. Although, ProActive has experienced personnel
in both the drug testing and investigative arena, there can be no assurance that
ProActive will become successful in marketing its services as a single source
provider on a national level. In addition, ProActive will face competition from
other companies which provide each of these services separately such as the
companies mentioned in the preceding subsections of this section "Competition"
under this caption "Risk Factors" as it relates to substance abuse testing
providers (including the laboratories which are vendors to ProActive), and local
or regional investigative firms or private investigators (including vendors to
ProActive) as it relates to background investigative services. Assuming that the
combined RSA/ProActive operations achieve national status as a single source
provider, there can be no assurance that existing or new companies will not
enter the national marketplace to compete with the combined RSA/ProActive
operations.
4. No Common Stock Dividends. USAT has not paid any cash dividends on the
USAT Common Stock and, based on the Company's cash requirements and continuing
losses, does not anticipate paying cash dividends on the USAT Common Stock in
the foreseeable future.
5. Depressive Effect on Market of Warrant or Option Exercises, Potential
144 Sales and Untimely Sales by Selling Stockholders. Any exercise of the
outstanding USAT Common Stock purchase warrants or stock options of USAT will
increase the shares available for public trading, which may depress the public
market price for the USAT Common Stock. USAT is required to maintain a current
prospectus in order to permit the sale of shares underlying certain of USAT's
warrants and USAT's options for any holder thereof who exercises. Because, prior
to the date hereof, there was, in the opinion of counsel to USAT, no such
prospectus complying with Section 10(a)(3) of the Securities Act, USAT filed the
Registration Statement to secure such a prospectus. Accordingly, because the
last of these USAT warrants and USAT options do not expire until November 15,
2000, the potential exercises and the subsequent sales thereof may act as an
overhang on the market for the USAT Common Stock for a long period.
As of August 31, 1996, 35,603,092 shares of the USAT Common Stock were
issued and outstanding, 2,173,474 of which were held by current or former
directors and executive officers of USAT and could only be sold pursuant to Rule
144 or another exemption under the Securities Act. Essentially, Rule 144 permits
the sale of (a) restricted securities (as such term is defined in Rule
144(a)(3)) held by any person after a two-year holding period and (b)
non-restricted securities held by affiliates of the issuer without any holding
period, in brokerage transactions and in an amount equal to the greater of the
average weekly reported trading volume during the prior four-week period or one
percent of the issuer's outstanding common shares during any three-month period.
If the stockholder has held the restricted securities for more than three years
and has not been an affiliate for more than three months prior to the
contemplated sale (the term "affiliate" being generally defined as a director,
executive officer or a beneficial owner of such number of the outstanding shares
of the USAT Common Stock as to be deemed in control of USAT), such stockholder
may sell pursuant to Rule 144(k) under the Securities Act without regard to such
a limitation on the number of shares.
As of August 31, 1996, there were also reserved for issuance: (a) 1,371,351
shares issuable upon the exercise at exercise prices ranging between $1.33 and
$4.00 per share of the September 1992 Warrants; (b) 61,250 shares issuable upon
the exercise at exercise prices ranging between $1.0625 and $4.00 per share of
the May 1994 Warrants; (c) 77,500 shares issuable upon the exercise at exercise
prices ranging between $2.00 and $2.50 per share of the January 1996 Warrants;
(d) 2,000,000 shares issuable upon the exercise at $2.00 per share of the
December 17 Warrants; (e) 185,207 shares issuable upon the conversion of the
shares of the Class A Preferred Stock, $.01 par value (the "Class A Preferred
Stock"); (f) 437,500 shares issuable upon the exercise at $2.375 per share of
the Options granted under the 1990 Option Plan originally expiring August 1,
2004, but now expiring the later of (i) 30 days after the date hereof or (ii) 90
days after (1) the optionee's employment terminated or terminates or (2), if the
optionee is not an employee, the directorship terminated; (g) 60,000 shares
issuable upon the exercise at $1.9375 per share of the November 15 Warrants
issued to then new directors of USAT and a consultant; (h) 700,000 shares
issuable upon the exercise of the
8
9
Director's Services Warrants (as to 400,000 shares at $1.9375 per share), as to
150,000 shares at $3.00 per share and as to 150,000 shares at $4.00 per share)
issued to a director in connection with his services in a capacity other than as
a director, including those related to the then pending private placement
pursuant to Regulation D under the Securities Act; (i) 300,000 shares issuable
upon the exercise at $3.125 per share of the Director's Second Services Warrant
issued to the same director for other services not in his capacity as a
director; (j) 235,000 shares issuable upon the exercise at exercise prices
ranging between $1.875 and $3.50 per share of the Employee Warrants issued to
employees of the Company; (k) 200,000 shares issuable upon the exercise at $2.00
per share of the December 27 Warrants issued to a then consultant to USAT for
his acting as spokesperson for the Company's alcohol and drug testing operations
(on April 18, 1996 he was named Chairman of the Board, Chief Executive Officer
and a director of USAT) and part of which he transferred to another employee of
USAT; (l) 200,000 shares issuable upon the exercise at $2.00 per share of the
March 31 Warrants issued to RSA as a consultant to ProActive in consideration of
its services rendered to ProActive operations (the warrant being divided among
the RSA shareholders after the acquisition of RSA by USAT); (m) 900,000 shares
issuable upon the exercise at $3.125 per share of the May 20 Warrants issued to
the RSA shareholders as part of the RSA purchase price; (n) 600,000 shares
issuable upon the exercise at $3.125 per share of the May 12 Warrant expiring
May 12, 1999 issued to the new President and Chief Operating Officer of USAT;
(o) 700,000 shares issuable upon the exercise at $2.4375 per share of the
February 26 Warrant issued to a consultant to USAT for financial public
relations services; (p) 100,000 shares issuable upon the exercise at $2.17 per
share of the October 19 Warrants issued to the placement agents for a private
placement pursuant to Regulation S under the Securities Act; and (q) 150,000
shares issuable upon the exercise at $2.25 per share of the January 29 Warrant
issued to an individual in connection with settlement of a litigation against
USAT. All of the foregoing Warrants and Options were granted at or above the
fair market value of the USAT Common Stock on the respective date of grant. Were
all of these 8,092,601 shares issuable upon the exercises of the foregoing
Warrants and Options, the 185,207 shares issuable upon the conversion of the
Class A Preferred Stock, and the shares described in the preceding paragraph
which could be sold pursuant to Rule 144, or a substantial number of the
foregoing shares, publicly sold over a short time period, the market price of
the USAT Common Stock could decline significantly because the market might lack
the capacity to absorb a large number of shares during a brief period. Such a
decline in market price may make the terms of any future financing more
difficult for USAT to consummate on a favorable basis.
In addition, were the purchasers of 2,000,000 shares of the USAT Common
Stock issued in the private placement as to which the final closing was held on
February 14, 1996 and the former RSA shareholders for the 500,000 shares of the
USAT Common Stock they received upon the acquisition of RSA by USAT to offer
such shares pursuant to this Prospectus, particularly if a substantial number of
these shares were offered for sale at the same time, such offerings could have
the same adverse impact as described in the preceding paragraph. The 500,000
shares issued to the RSA shareholders were registered under the Securities Act
as "Acquisition Shares" in the January 1992 Registration Statement, but required
a post-effective amendment to the January 1992 Registration Statement being
declared effective under the Securities Act for such shareholders to resell.
To the extent that the Good Ideas Merger is consummated, shares of the USAT
Common Stock will be issued to the Good Ideas Minority Stockholders. To the
extent that the U.S. Drug Merger is consummated, shares of the USAT Common Stock
will be issued to the minority stockholders of U.S. Drug. The aggregate of these
shares of the Common Stock issued on such transactions will, with limited
exceptions, be freely tradeable and, if a substantial number of these shares
were offered for sale at the same time, such offerings could have the same
adverse impact as described in the second preceding paragraph.
6. Technological Changes. The substance abuse testing industry is a
technological sensitive industry in that companies are constantly developing new
methods and making changes to current methods for substance abuse detection in
order to remain competitive. USAT competes, and, when its development stage for
a saliva based test and a urine based test are completed, U.S. Drug will
compete, with larger companies such as those named under the section
"Competition" under this caption "Risk Factors," many of which have
substantially greater financial resources available to them to invest in the
research and development of their products than USAT and U.S. Drug. These
competitors may develop products in the future which may render USAT's and
9
10
U.S. Drug's products obsolete or non-competitive from a pricing point of view.
To remain competitive, USAT and U.S. Drug may require substantial financial
resources for personnel and other costs to conduct research and update current
products to reflect the technological advances; however, such financial
resources may not be available. In the alternative, depending on the progress in
the drug testing research and development program (including the current
feasibility study), U.S. Drug may at a later date seek a major pharmaceutical or
other company to assist in the development program and, depending on the
financial arrangements to be negotiated, such development partner may seek
marketing rights to the products when and if successfully developed. Although
such a partner may reduce certain current expenditures, it may later, by
assuming marketing rights, reduce prospective revenues to U.S. Drug. Because of
the stage of development of the product and the fact that no search or
negotiations are currently being conducted, management believes that it is
currently too speculative to anticipate U.S. Drug's competitive position based
on the presence of a development and/or marketing partner. See the section "Need
for Financing" under this caption "Risk Factors."
7. Market Limitation for Alcohol Testing Products. The potential markets
for USAT's alcohol testing products may be substantially limited to the ones in
which it currently sells law enforcement, correctional facilities, medical and
clinical facilities, alcohol treatment centers and emergency rooms. This market
insofar as alcohol testing is concerned may be saturated and the opportunity for
growth limited; however, management of USAT believes that the demand for alcohol
testing could grow in the industrial market, in which USAT does some current
selling, on a broader basis as did the demand for drug testing at an earlier
date. There can be no assurance that such growth will occur or that, if the
growth occurs, USAT will successfully penetrate the industrial market.
8. Possible Market Making Restrictions. Unless granted an exemption by the
Commission from Rule 10b-6 under the Exchange Act, any soliciting broker-dealers
will be prohibited from engaging in any market making activities regarding
USAT's securities for two business days prior to any solicitation activity on
behalf of the Selling Stockholders or the termination of any right that
soliciting broker-dealers may have to receive a fee for the exercise of the
Warrants following such solicitation. As a result, soliciting broker-dealers may
be unable to continue to provide a market for USAT's securities during certain
periods while the Warrants or the Options are exercisable.
DILUTION
As of June 30, 1996, there were 35,353,092 shares of the USAT Common Stock
outstanding and the net tangible book value of USAT was $149,052 or $.004 per
share of the USAT Common Stock. Net tangible book value per share of the USAT
Common Stock is the tangible assets of USAT less all liabilities and the Class A
Preferred Stock liquidation preference divided by the number of shares of the
USAT Common Stock outstanding. If all shares of the Class A Preferred Stock are
converted into shares of the USAT Common Stock, USAT would have 35,538,299
shares of the USAT Common Stock outstanding with a net tangible book value of
$354,837 or $.01 per share of the USAT Common Stock. If all of the Warrants and
the Options were exercised, USAT would have 43,890,900 shares of the USAT Common
Stock outstanding with a net tangible book value of $20,621,776 or $.47 per
share of the USAT Common Stock.
10
11
The following table reflects the dilution incurred by the various holders
of the Warrants and the Options after the exercise of their respective Warrants
and Options and assuming the conversion of the Class A Preferred Stock as
described in the preceding paragraph:
Net tangible book value per share before Warrant exercise.......... $ .01
Dilution per share to $1.0625 Warrantholders....................... $1.0525
Dilution per share to $1.87 Warrantholders......................... $1.86
Dilution per share to $1.875 Warrantholders........................ $1.865
Dilution per share to $1.9375 Warrantholders....................... $1.9275
Dilution per share to $2.00 Warrantholders......................... $1.99
Dilution per share to $2.17 Warrantholders......................... $2.16
Dilution per share to $2.1875 Warrantholders....................... $2.1775
Dilution per share to $2.19 Warrantholders......................... $2.18
Dilution per share to $2.22 Warrantholders......................... $2.21
Dilution per share to $2.25 Warrantholders......................... $2.24
Dilution per share to $2.3125 Warrantholders....................... $2.3025
Dilution per share to $2.375 Optionholders......................... $2.365
Dilution per share to $2.4375 Warrantholders....................... $2.4275
Dilution per share to $2.50 Warrantholders......................... $2.49
Dilution per share to $2.8125 Warrantholders....................... $2.8025
Dilution per share to $3.00 Warrantholders......................... $2.99
Dilution per share to $3.125 Warrantholders........................ $3.115
Dilution per share to $3.50 Warrantholders......................... $3.49
Dilution per share to $4.00 Warrantholders......................... $3.99
- ---------------
(1) Shares of the USAT Common Stock are issuable upon the exercise of the
Warrants and the Options are at the following exercise prices per share:
15,000 at $1.0625; 92,795 at $1.87; 10,000 at $1.875; 465,000 at $1.9375;
2,440,000 at $2.00; 100,000 at $2.17; 36,000 at $2.1875; 5,000 at $2.19;
1,175,856 at $2.22; 150,000 at $2.25; 15,000 at $2.3125; 437,500 at $2.375;
700,000 at $2.4375; 18,750 at $2.50; 5,000 at $2.8125; 150,000 at $3.00;
1,800,000 at $3.125; 194,000 at $3.50; and 150,000 at $4.00.
Those investors purchasing shares of the USAT Common Stock from the Selling
Stockholders would have a dilution of $2.5875 per share based upon a market
price of $2.6875 on September 3, 1996.
USE OF PROCEEDS
The net proceeds arising from the exercise of the Warrants and the Options
is not ascertainable because there is no assurance of any such exercise. USAT
will use these proceeds, if any, for general corporate purposes including
salaries and working capital in no allocatable order of priority. If all
Warrants and Options whose underlying shares are being offered by this
Prospectus were exercised, USAT would realize net proceeds of $20,036,514. If
less than all of the Warrants and the Options are exercised, working capital
would be reduced or eliminated and the funds received would be applied without
priority to advertising and marketing programs. USAT will receive no proceeds
from the subsequent sales by the Selling Stockholders of the shares of the USAT
Common Stock to be issued to them upon the exercise of the Warrants and Options.
SELLING STOCKHOLDERS
The table below sets forth (1) the number of shares of the USAT Common
Stock (an aggregate of 2,000,000 shares) registered under the Securities Act
pursuant to the Registration Statement and to be offered by the Selling
Stockholders named in the following table pursuant to this Prospectus; (2) the
number of shares of the USAT Common Stock owned beneficially by each such
Selling Stockholder before and after such offering; and (3) the percentage of
beneficial ownership before and after the offering. The shares
11
12
reported in the table as being beneficially owned reflect or include (1) an
aggregate of 2,000,000 shares of the USAT Common Stock purchased in a private
placement pursuant to Regulation D under the Securities Act, the closings under
which were held between December 18, 1995 and February 14, 1996, and (2) an
aggregate of 2,000,000 shares of the USAT Common Stock issuable upon the
exercise of the December 17 Warrants. The shares issuable upon the exercise of
the December 17 Warrants have been registered under the Securities Act pursuant
to the Registration Statement for issuance by USAT and, in the opinion of Gold &
Wachtel, LLP, counsel to USAT, because none of such holders is an affiliate of
USAT as such term is defined in Rule 405 under the Securities Act, none of the
holders are required, upon resale after exercise, to deliver a prospectus naming
such holder as a Selling Stockholder and otherwise complying with Section
10(a)(3) under the Securities Act.
NUMBER OF SHARES PERCENTAGE(1)
------------------------------- -------------------
NAME BEFORE OFFERED AFTER BEFORE AFTER
- --------------------------------------------- ------- ------- ------- ------- -------
Agia, Mallis & Pautler Profit Sharing Plan... 100,000 50,000 50,000 nil nil
Mallis Limited Partnership................... 500,000 250,000 250,000 nil nil
Schwartz Family Limited Partnership.......... 200,000 100,000 150,000 nil nil
John and Arthur Schwartz..................... 200,000 100,000 100,000 nil nil
Martin W. Rosen.............................. 500,000 250,000 250,000 1.4 nil
Thomas and H. Lawrence
Kaufman Family Partnership................. 100,000 50,000 50,000 nil nil
Frank and Patricia Musolino.................. 800,000 400,000 400,000 2.2 1.1
Henry H. Ramseur............................. 100,000 50,000 50,000 nil nil
Arthur Gordon................................ 100,000 50,000 50,000 nil nil
Harold S. Rosen.............................. 100,000 50,000 50,000 nil nil
Walter Schlessel............................. 100,000 50,000 50,000 nil nil
Jack and Anita Elias......................... 100,000 50,000 50,000 nil nil
Sanford Miller............................... 500,000 250,000 250,000 1.4 nil
Townsview Properties Limited................. 100,000 50,000 50,000 nil nil
Martin B. Perlman............................ 100,000 50,000 50,000 nil nil
Richard R. Kreitler.......................... 100,000 50,000 50,000 nil nil
Craig and Barbara Wertkin.................... 100,000 50,000 50,000 nil nil
Craig S. Wertkin............................. 100,000 50,000 50,000 nil nil
David E. Leven............................... 100,000 50,000 50,000 nil nil
- ---------------
(1) The percentages computed in this column of the table are based upon
35,603,092 shares of the USAT Common Stock outstanding on August 31, 1996
and effect being given, where appropriate, pursuant to Rule 13d-3(d)(1)(i)
under the Exchange Act, to shares issuable upon the exercise of the Warrants
and the Options which are currently exercisable or exercisable within 60
days of August 31, 1996.
The table below sets forth (1) the number of shares of the USAT Common
Stock (an aggregate of 5,358,205 shares) registered under the Securities Act
pursuant to the Registration Statement and the January 1992 Registration
Statement and to be offered by those of the Selling Stockholders named in the
following table pursuant to this Prospectus after, except for an aggregate of
3,000,300 shares of the USAT Common Stock, the exercise of the New Warrants
granted to him or her; (2) the number of shares of the USAT Common Stock owned
beneficially by each such Selling Stockholder before and after such offering;
and (3) the percentage of beneficial ownership before and after the offering.
12
13
NUMBER OF SHARES PERCENTAGE(1)
----------------------------------------- -------------------
NAME BEFORE OFFERED AFTER BEFORE AFTER
- ---------------------------------- --------- --------- --------- ------- -------
Alan I. Goldman(2)................ 10,000(3) 10,000(3) 0 nil 0
Peter M. Mark(2).................. 557,600(3) 10,000(3) 547,600 1.6 1.5
John C. Lawn(2)................... 10,000(3) 10,000(3) 0 nil 0
Linda H. Masterson(4)............. 610,000(5) 610,000(5) 0 1.7 0
Michael McCord(6)................. 413,808(7) 10,000(7) 403,808 1.2 1.1
Lee S. Rosen(2)................... 1,478,648(8) 1,010,000(8) 468,648 4.0 1.3
Robert Stutman(9)................. 971,500(10) 971,500(10) 0 2.7 0
Brian L. Stutman.................. 636,500(11) 636,500(11) 0 1.8 0
Sandra DeBow...................... 57,000(12) 57,000(12) 0 nil 0
Michael Rochelle.................. 120,000(13) 120,000(13) 0 nil 0
Kimberly Rochelle................. 40,000(14) 40,000(14) 0 nil 0
Joseph Bradley(15)................ 10,000(16) 10,000(15) 0 nil 0
Erica Kline....................... 5,000(17) 5,000(17) 0 nil 0
Shoreh Moheb...................... 10,000(18) 10,000(18) 0 nil 0
Patricia Starling................. 10,000(19) 10,000(19) 0 nil 0
Greg Uyeda........................ 3,000(20) 3,000(20) 0 nil 0
Leonard DePino.................... 3,000(20) 3,000(20) 0 nil 0
Steven Kline...................... 68,000(21) 55,000(21) 13,000 nil nil
Christine Clearwater.............. 30,000(22) 30,000(22) 0 nil 0
William Current................... 39,000(23) 39,000(23) 0 nil 0
Brik Bradford..................... 30,000(24) 30,000(24) 0 nil 0
Gary Geddig....................... 5,000(25) 5,000(25) 0 nil 0
Martin Walsh...................... 5,000(26) 5,000(26) 0 nil 0
Robert E. Reed.................... 5,000(26) 5,000(26) 0 nil 0
Jonathan J. Pallin................ 150,000(27) 150,000(27) 0 nil 0
Lyle K. Pfeffer................... 700,000(28) 700,000(28) 0 1.9 0
Pacific Miners.................... 50,000(29) 50,000(29) 0 nil 0
Aires Peak........................ 50,000(29) 50,000(29) 0 nil 0
Michael J. Witham(30)............. 462,750(31) 315,000(31) 147,750(31) 1.3 nil
James C. Witham(32)............... 1,342,030(33) 283,530(33) 1,058,500(33) 3.8 3.0
Karen B. Laustsen(34)............. 278,925(35) 76,925(35) 202,000(35) nil nil
Roger Tatum....................... 17,500(36) 17,500(36) 0 nil 0
George Berger(37)................. 41,125(38) 20,250(38) 20,875(38) nil nil
- ---------------
(1) The percentages computed in this column of the table are based upon
35,603,092 shares of the USAT Common Stock outstanding on August 31, 1996
and effect being given, where appropriate, pursuant to Rule 13d-3(d)(1)(i)
under the Exchange Act, to shares issuable upon the exercise of the
Warrants and the Options which are currently exercisable or exercisable
within 60 days of August 31, 1996.
(2) A director of USAT.
(3) The shares reported in this table include or reflect 10,000 shares of the
USAT Common Stock issuable upon the exercise at $1.9375 per share of a
November 15 Warrant issued to the holder as a director of USAT who, at the
date of grant, was not employed by USAT or any subsidiary thereof.
(4) Ms. Masterson, a director of USAT since September 26, 1995, became its
President and Chief Operating Officer effective May 13, 1996.
(5) The shares reported in the table reflect (a) 10,000 shares of the USAT
Common Stock issuable upon the exercise at $1.9375 per share of a November
15 Warrant issued to her as a director of USAT on the same basis as
described in note (3) to the table; and (b) 600,000 shares issuable upon
the exercise at
13
14
$3.125 per share of the May 12 Warrant issued pursuant to Ms. Masterson's
terms of employment. The May 12 Warrant is currently exercisable as to
50,000 shares and becomes exercisable as to 100,000 shares at the end of
her first year of employment and as to 150,000 shares at the end of each of
her second, third and fourth years of employment. She has three years, from
the date each installment becomes exercisable, to exercise as to such
installment, so that the expiration date for the last installment is May
12, 2003.
(6) A consultant to the USAT Board.
(7) The shares reported in the table include 10,000 shares of the USAT Common
Stock issuable upon the exercise at $1.9375 per share of a November 15
Warrant issued to him as a consultant to the Board of USAT.
(8) The shares reported in the table include (a) 10,000 shares of the USAT
Common Stock issuable upon the exercise at $1.9375 per share of a November
15 Warrant issued to Mr. Rosen on the same basis as those described in note
(3) to this table; (b) 400,000 shares issuable upon the exercise at $1.9375
per share of a Director's Services Warrant; (c) 150,000 shares upon the
exercise at $3.00 per share of a Director's Services Warrant; (d) 150,000
shares upon the exercise at $4.00 per share of a Director's Services
Warrant; and (e) 300,000 shares issuable upon the exercise at $3.125 per
share of the Director's Second Services Warrant issued to Mr. Rosen as
consideration for assisting in the exercise of USAT Common Stock purchase
warrants. The Director's Services Warrants described in (b), (c) and (d)
were issued to Mr. Rosen as consideration for his services, including those
related to the private placement consummated in February 1996. 50,000 of
the shares subject to each of the Director's Services Warrants described in
(c) and (d) may be forfeited if none of the December 17 Warrants are
exercised and may be reduced in the number of shares which may be exercised
pro rata to the exercise of the December 17 Warrants.
(9) Mr. Stutman was elected Chairman of the Board and a director of USAT and
designated as its Chief Executive Officer on April 18, 1996.
(10) The shares reported in the table include (a) 127,500 shares of the USAT
Common Stock issuable upon the exercise at $2.00 per share of a December 13
Warrant issued to him for his consulting services; (b) 105,500 shares
issuable upon the exercise at $2.00 per share of a March 31 Warrant issued
to him when the RSA Consulting Warrant to purchase 200,000 shares to be
issued to RSA was divided among the former RSA shareholders; (c) 474,750
shares issuable upon the exercise at $3.125 per share of a May 20 Warrant
issued to him in exchange for his ownership interest in RSA; and (d)
263,750 shares of the Acquisition Shares also issued to him in exchange for
his ownership interest in RSA.
(11) The shares reported in the table reflect (a) 72,500 shares of the USAT
Common Stock issuable upon the exercise at $2.00 per share of a December 13
Warrant transferred to him by Robert Stutman, who received the same
initially for the latter's consulting services as described in Note (10) to
the table; (b) 70,500 shares issuable upon the exercise at $2.00 per share
of a March 31 Warrant issued to him when the RSA Consulting Warrant was
divided among the former RSA shareholders; (c) 317,250 shares issuable upon
the exercise at $3.125 per share of a May 20 Warrant issued to him in
exchange for his ownership interest in RSA; and (d) 176,250 shares of the
Acquisition Shares also issued to him in exchange for his ownership
interest in RSA.
(12) The shares reported in the table reflect (a) 4,000 shares of the USAT
Common Stock issuable upon the exercise at $2.00 per share of a March 31
Warrant issued to her when the RSA Consulting Warrant was divided among the
former RSA shareholders; (b) 18,000 shares issuable upon the exercise at
$3.125 per share of a May 20 Warrant issued to her in exchange for her
ownership interest in RSA; (c) 10,000 shares of the Acquisition Shares also
issued to her in exchange for her ownership interest in RSA; and (d) 25,000
shares issuable upon the exercise at $3.50 per share of an Employee Warrant
which becomes exercisable as to 6,250 shares on each anniversary date of
June 10, 1996 over a four-year period. The holder has three years from the
date the Employee Warrant becomes exercisable as to an installment to
exercise as to such installment, so that the expiration date for the last
installment will be June 9, 2003.
(13) The shares reported in the table reflect (a) 15,000 shares of the USAT
Common Stock issuable upon the exercise at $2.00 per share of a March 31
Warrant issued to him when the RSA Consulting Warrant
14
15
was divided among the former RSA shareholders; (b) 68,500 shares issuable
upon the exercise at $3.125 per share of a May 20 Warrant issued to him in
exchange for his ownership interest in RSA; and (c) 37,500 shares of the
Acquisition Shares also issued to him in exchange for his or her ownership
interest in RSA.
(14) The shares reported in the table reflect (a) 5,000 shares of the USAT
Common Stock issuable upon the exercise at $2.00 per share of a March 31
Warrant issued to her when the RSA Consulting Warrant was divided among the
former RSA shareholders; (b) 22,500 shares issuable upon the exercise at
$3.125 per share of a May 20 Warrant issued to her in exchange for her
ownership interest in RSA; and (c) 12,500 shares of the Acquisition Shares
also issued to her in exchange for her ownership interest in RSA.
(15) Treasurer, Acting Chief Financial Officer and Acting Chief Accounting
Officer of USAT.
(16) The shares reported in the table reflect 10,000 shares of the USAT Common
Stock issuable upon the exercise at $1.875 per share of an Employee Warrant
expiring January 2, 1999.
(17) The shares reported in the table reflect 5,000 shares of the USAT Common
Stock issuable upon the exercise at $2.8125 per share of an Employee
Warrant expiring August 27, 1998.
(18) The shares reported in the table reflect (a) 5,000 shares of the USAT
Common Stock issuable upon the exercise at $1.9375 per share of an Employee
Warrant expiring January 31, 1999 and (b) 5,000 shares issuable upon the
exercise at $3.50 per share of an Employee Warrant which becomes
exercisable as to 1,250 shares on each anniversary date of May 2, 1996 over
a four-year period. The holder has three years, from the date the Employee
Warrant becomes exercisable as to an installment, to exercise as to such
installment, so that the expiration date for the last installment is May 1,
2003. She also is eligible to receive a Common Stock purchase warrant, also
exercisable at $3.50 per share, to acquire 5,000 shares if certain
performance criteria are met. The underlying shares subject to such warrant
are not being registered under the Securities Act in the Registration
Statement and, accordingly, the shares are not being offered for resale
pursuant to this Prospectus.
(19) The shares reported in the table reflect 10,000 shares of the USAT Common
Stock issuable upon the exercise at $2.00 per share of an Employee Warrant
expiring December 27, 1998.
(20) The shares reported in the table reflect 3,000 shares of the USAT Common
Stock issuable upon the exercise at $2.1875 per share of an Employee
Warrant expiring July 19, 1999.
(21) The shares reported in the table as being beneficially owned reflect 3,000
shares of the USAT Common Stock allocated to this officer and employee of a
subsidiary on May 3, 1996; (b) 5,000 shares issuable upon the exercise at
$2.3125 per share of an Employee Warrant expiring July 17, 1998 and being
offered pursuant to this Prospectus as indicated in the table; (c) 10,000
shares issuable upon the exercise at $2.3125 per share of a January 1996
Warrant expiring July 17, 1998, which shares are being offered for resale
by the holder after exercise pursuant to this Prospectus as indicated in
the fourth table under this caption "Selling Stockholders;" and (d) 50,000
shares issuable upon the exercise at $3.50 per share of an Employee Warrant
which becomes exercisable as to 12,500 shares on each anniversary date of
May 3, 1996 over a four-year period and which 50,000 shares are being
offered pursuant to this Prospectus as indicated in the table. The holder
has three years, from the date the Employee Warrant becomes exercisable as
to an installment, to exercise as to such installment, so that the
expiration date for the last installment is May 2, 2003. He also is
eligible to receive a Common Stock purchase Warrant, also exercisable at
$3.50 per share, to acquire 20,000 shares if certain performance criteria
are met. The underlying shares subject to such warrant are not being
registered under the Securities Act in the Registration Statement and,
accordingly, the shares are not being offered for resale pursuant to this
Prospectus.
(22) The shares reported in the table reflect 30,000 shares of the USAT Common
Stock issuable upon the exercise at $3.50 per share of an Employee Warrant
which becomes exercisable as to 7,500 shares on each anniversary date of
May 15, 1996 over a four-year period. The holder has three years, from the
date the Employee Warrant becomes exercisable as to an installment, to
exercise as to such installment, so that the expiration date for the last
installment is May 14, 2003.
15
16
(23) The shares reported in the table reflect 39,000 shares of the USAT Common
Stock issuable upon the exercise at $3.50 per share of an Employee Warrant
which becomes exercisable as to 9,750 shares on each anniversary date of
May 1, 1996 over a four-year period. The holder has three years, from the
date the Employee Warrant becomes exercisable as to an installment, to
exercise as to such installment, so that the expiration date for the last
installment is April 30, 2003. He also is eligible to receive Common stock
purchase warrants, also exercisable at $3.50 per share, to acquire
additional shares (in blocks of 10,000 shares) if certain performance
criteria are not. The underlying shares subject to these warrants are not
being registered under the Securities Act and, accordingly, are not being
offered for resale by the holder pursuant to this Prospectus.
(24) The shares reported in the table reflect 30,000 shares of the USAT Common
Stock issuable upon the exercise at $3.50 per share of an Employee Warrant
which becomes exercisable as to 7,500 shares on each anniversary date of
April 30, 1996 over a four-year period. The holder has three years, from
the date the Employee Warrant becomes exercisable as to an installment, to
exercise as to such installment, so that the expiration date for the last
installment is April 29, 2003.
(25) The shares reported in the table reflect 5,000 shares of the USAT Common
Stock issuable upon the exercise at $3.50 per share of an Employee Warrant
which becomes exercisable as to 1,250 shares on each anniversary date of
July 19, 1996 over a four-year period. The holder has three years, from the
date the Employee Warrant becomes exercisable as to an installment, to
exercise as to such installment, so that the expiration date for the last
installment is July 18, 2003.
(26) The shares reported in the table reflect 5,000 shares of the USAT Common
Stock issuable upon the exercise at $3.50 per share on each anniversary
date of July 8, 1996 over a four-year period. The holder has three years,
from the date the Employee Warrant becomes exercisable as to an
installment, to exercise as to such installment, so that the expiration
date for the last installment is July 7, 2003.
(27) The shares reported in the table reflect issuable upon the exercise at
$2.25 per share of the January 29 Warrant issued to the Selling Stockholder
upon settlement of litigation.
(28) The shares reported in the table reflect shares issuable upon the exercise
at $2.4375 of the February 26 Warrant issued to the Selling Stockholder for
his financial public relations consulting services.
(29) The shares reported in the table reflect shares issuable upon the exercise
at $2.17 per share of a October 19 Warrant issued to the Selling
Stockholder as a placement fee for an offering by USAT pursuant to
Regulation S under the Securities Act.
(30) A former Vice President of USAT.
(31) The shares reported in the table as being beneficially owned reflect (a)
315,000 shares of the USAT Common Stock received upon the exercises of a
January 1992 Warrant and being offered pursuant to this Prospectus as
indicated in this table; (b) 60,000 shares issuable at $2.375 per share
upon the exercise of an Option and being offered pursuant to this
Prospectus as indicated in the third table under this caption "The Selling
Stockholders;" and (c) 87,750 other shares.
(32) The former Chairman, President and Chief Executive Officer and a former
director of USAT.
(33) The shares reported in the table reflect (a) 283,530 shares of the USAT
Common Stock received upon the exercise of January 1992 Warrant and being
offered pursuant to this Prospectus as indicated in this table; (b) 180,000
shares issuable upon the exercise of an Option and being offered pursuant
to this Prospectus as indicated in the third table under this caption
"Selling Stockholders;" and (c) 878,500 other shares.
(34) A former Executive Vice President and director of USAT.
(35) The shares reported in the table reflect (a) 76,925 shares of the USAT
Common Stock received upon the exercise of a January 1992 Warrant and being
offered pursuant to this Prospectus as indicated in this table; (b) 100,000
shares issuable upon the exercise of an Option and being offered pursuant
to this Prospectus as indicated in the third table under this caption
"Selling Stockholders;" and (c) 102,000 other shares.
16
17
(36) The shares reported in the table reflect shares of the USAT Common Stock
received upon the exercise of a January 1992 Warrant and being offered
pursuant to this Prospectus as indicated in this table.
(37) A former Secretary of USAT.
(38) The shares reported in the table reflect (a) 20,250 shares of the USAT
Common Stock received upon the exercise of a January 1992 Warrant and being
offered pursuant to this Prospectus as indicated in this table; (b) 5,000
shares issuable upon the exercise of an Option and being offered pursuant
to this Prospectus as indicated in the third table under this caption
"Selling Stockholders;" and (c) 15,875 other shares.
The table below sets forth (1) the number of shares of the USAT Common
Stock (an aggregate of 437,500 shares) registered under the Securities Act
pursuant to the January 1996 Registration Statement and to be offered by each of
the Selling Stockholders named in the following table pursuant to this
Prospectus after the exercise at $2.375 per share of the Option granted to him
or her pursuant to the 1990 Option Plan, (2) the number of shares of the USAT
Common Stock beneficially owned by each such Selling Stockholder before and
after such offering and (3) the percentage of beneficial ownership before and
after the offering.
NUMBER OF SHARES PERCENTAGE(1)
------------------------------------------- -------------------
NAME BEFORE OFFERED AFTER BEFORE AFTER(2)
- ----------------------------- --------- ------- --------- ------ --------
James C. Witham(2)........... 1,342,030(3) 180,000(3) 1,162,030(3) 3.8 3.3
Gary S. Wolff(4)............. 105,000(5) 80,000(5) 25,000(5) nil nil
Karen B. Laustsen(6)......... 278,925(7) 100,000(7) 178,925(7) nil nil
William DiTuro(8)............ 37,600(9) 12,500(9) 25,100(9) nil nil
Michael J. Witham(10)........ 462,750(11) 60,000(11) 402,750(11) nil nil
George Berger(12)............ 41,125(13) 5,000(13) 36,125(13) nil nil
- ---------------
(1) The percentages computed in this column of the table are based upon
35,603,092 shares of the USAT Common Stock outstanding on August 31, 1996
and effect being given, where appropriate, pursuant to Rule 13d-3(d)(1)(i)
under the Exchange Act, to shares issuable upon the exercise of the Options
and the Warrants, all of which insofar as they relate to Selling
Stockholders in the table are currently exercisable.
(2) The former Chairman, President and Chief Executive Officer and a former
director of USAT.
(3) The shares reported in the table reflect (a) 180,000 shares of the USAT
Common Stock issuable upon the exercise of an Option and being offered
pursuant to this Prospectus as indicated in this table; (b) 283,530 shares
received upon the exercise of a January 1992 Warrant and being offered
pursuant to this Prospectus as indicated in the second table under this
caption "Selling Stockholders"; and (c) 878,500 other shares.
(4) The former Treasurer, Chief Financial Officer and Chief Accounting Officer
of USAT.
(5) The shares reported in the table reflect (a) 80,000 shares of the USAT
Common Stock issuable upon the exercise of an Option and being offered
pursuant to this Prospectus as indicated in this table; (b) an aggregate of
25,000 shares issuable upon the exercise of May 1994 Warrants and being
offered pursuant to this Prospectus as indicated in the fourth table under
this caption "Selling Stockholders;" and (c) 144,226 other shares.
(6) A former Executive Vice President and director of USAT.
(7) The shares reported in the table reflect (a) 100,000 shares of the USAT
Common Stock issuable upon the exercise of an Option and being offered
pursuant to this Prospectus as indicated in this table; (b) 76,925 shares
of the USAT Common Stock received upon the exercise of a January 1992
Warrant and being offered pursuant to this Prospectus indicated in the
second table under this caption "Selling Stockholders;" and (c) 102,000
other shares.
(8) A former director of USAT.
(9) The shares reported in the table reflect (a) 12,500 shares of the USAT
Common Stock issuable upon the exercise of an Option and being offered
pursuant to this Prospectus as indicated in this table;
17
18
(b) 10,000 shares issuable upon the exercise of a May 1994 Warrant and
being offered pursuant to this Prospectus as indicated in the fourth table
under this caption "Selling Stockholders;" and (c) 15,100 other shares.
(10) A former Vice President of USAT.
(11) The shares reported in the table reflect (a) 60,000 shares of the USAT
Common Stock issuable upon the exercise of an Option and being offered
pursuant to this Prospectus as indicated in this table; (b) 315,000 shares
received upon prior exercises of a January 1992 Warrant and being offered
pursuant to this Prospectus as indicated in the second table under this
caption "Selling Stockholders;" and (c) 87,750 other shares.
(12) A former Secretary of USAT.
(13) The shares reported in the table reflect (a) 5,000 shares of the USAT
Common stock issuable upon the exercise of an Option and being offered
pursuant to this Prospectus as indicated in this table; (b) 20,250 shares
received upon the exercise of a January 1992 Warrant and being offered
pursuant to this Prospectus as indicated in the second table under this
caption "Selling Stockholders;" and (c) 15,875 other shares.
The table below sets forth (1) the number of shares of the USAT Common
Stock (an aggregate of 138,750 shares) issuable upon the exercise of the May
1994 Warrants (61,250 shares) and the January 1996 Warrants (77,500 shares),
which shares were registered under the Securities Act pursuant to the May 1994
Registration Statement and the January 1996 Registration Statement and are being
offered pursuant to this Prospectus by the Selling Stockholders named in the
table after the exercise of the May 1994 Warrants and the January 1996 Warrants;
(2) the exercise price of the May 1994 Warrants and the January 1996 Warrants;
and (3) the expiration dates of the May 1994 Warrants and the January 1996
Warrants. None of the Selling Stockholders named in the table owns 1% or more of
the out-standing shares of the USAT Common Stock before or after this offering.
During the past three years, none of the Selling Stockholders had any
relationship with USAT other than as a securityholder of USAT except as
indicated in a note to the table.
NUMBER OF EXERCISE EXPIRATION
NAME SHARES PRICE DATE
- -------------------------------------------------- --------- -------- ----------
Gary S. Wolff(1).................................. 15,000(2) $1.06 11/1/97
10,000 $4.00 5/17/97
Glenn A. Bergenfield(3)........................... 10,000(4) $4.00 5/17/97
William DiTuro(3)................................. 10,000(2) $4.00 5/17/97
Clifford Bennett(4)............................... 5,000 $2.19 9/1/98
7,500 $2.50 9/1/98
Debra Sands(5).................................... 5,000 $2.1875 7/19/99
James Velnosky(6)................................. 10,000 $2.00 12/31/99
10,000 $2.00 12/31/2000
10,000 $2.00 12/31/2001
Norman Shifrin.................................... 9,625 $2.1875 7/19/99
Arthur Meisner.................................... 5,750 $2.1875 7/19/99
Irmgard Kaufhold.................................. 9,625 $2.1875 7/19/99
James Whelan(5)................................... 11,250 $2.50 4/15/98
Steven Kline(6)................................... 10,000 $2.3125 7/17/99
- ---------------
(1) The former Treasurer, Chief Financial Officer and Chief Accounting Officer
of USAT.
(2) See the third table under this caption "Selling Stockholders" for
information as to his Option also being offered pursuant to this Prospectus.
(3) A former director of USAT.
18
19
(4) The shares reported in the table do not include 12,500 shares received upon
the exercise of an Option and being offered pursuant to this Prospectus as
indicated in the fifth table under this caption "Selling Stockholders."
(5) A former employee of USAT or a subsidiary of USAT.
(6) Employed by USAT or one of its subsidiaries.
The table below sets forth (1) the number of shares of the USAT Common
Stock (an aggregate of 1,371,351 shares) issuable upon the exercise of the
September 1992 Warrants, which shares were registered under the Securities Act
pursuant to the September 1992 Registration Statement and are being offered
pursuant to this Prospectus by the Selling Stockholders named in the table after
the exercise of the September 1992 Warrants; (2) the exercise prices of the
September 1992 Warrants; and (3) the expiration dates of the September 1992
Warrants. None of the Selling Stockholders named in the table owns 1% or more of
the outstanding shares of the USAT Common Stock before or after this offering.
During the past three years, none of these Selling Stockholders had any
relationship with USAT other than as a securityholder of USAT except as
indicated in a note to the table.
NUMBER OF EXERCISE EXPIRATION
NAME SHARES PRICE DATE
- ---------------------------------------------------- --------- -------- ----------
David Brooks........................................ 7,700 $3.50 9/16/97
Herbert Stein....................................... 75,000 $4.00 12/31/97
JGC, Inc.(1)........................................ 75,295 $1.87 12/17/97
Arthur Klusner(1)................................... 17,500 $1.87 12/17/97
WG Trading Company LP............................... 225,000 $2.22 10/31/96
Guli R. Rajani...................................... 56,250 $2.22 10/31/96
Norman Shifrin...................................... 149,720 $2.22 10/31/96
Ruby Balter......................................... 56,250 $2.22 10/31/96
Arnold Balter, IRA Rollover......................... 56,250 $2.22 10/31/96
Lori Balter......................................... 14,062 $2.22 10/31/96
Joan Kaufman........................................ 28,125 $2.22 10/31/96
Douglas Black....................................... 126,562 $2.22 10/31/96
Irmgard Kaufhold.................................... 35,705 $2.22 10/31/96
Harold Edrich....................................... 6,060 $2.22 10/31/96
Jay M. Kulkin....................................... 14,062 $2.22 10/31/96
Lee Frank........................................... 70,312 $2.22 10/31/96
Jeffrey S. Podell................................... 14,062 $2.22 10/31/96
Mitchell Weisner.................................... 28,125 $2.22 10/31/96
Phillip A. Witt..................................... 14,062 $2.22 10/31/96
Richard Vitello..................................... 14,062 $2.22 10/31/96
Morris B. Black..................................... 225,000 $2.22 10/31/96
Gabriel Mark Cerrone................................ 14,062 $2.22 10/31/96
Rosalia Cerrone..................................... 28,125 $2.22 10/31/96
Tuck Trainor........................................ 20,000 $1.33 10/31/96
- ---------------
(1) The holder received its September 1992 Warrant as underwriting compensation.
The table below sets forth the number of shares (an aggregate of 451,969)
of the USAT Common stock being offered by certain of the Selling Stockholders
pursuant to this Prospectus, the shares having been acquired by the stockholder
after the exercise of a May 1994 Warrant (14,500 shares), a January 1996 Warrant
(24,250 shares), a September 1992 Warrant (400,719 shares) or an Option (12,500
shares). None of the Selling Stockholders named in the table owns 1% or more of
the outstanding shares of the USAT Common Stock before or after this offering.
During the past three years none of these Selling Stockholders
19
20
had any relationship with USAT other than as a securityholder of USAT except as
indicated in a note to the table.
NUMBER OF
NAME SHARES TYPE OF WARRANT
------------------------------------------------- --------- ---------------
Jock Cameron(1).................................. 5,000 January 1996
Douglas Allen(1)................................. 10,000 May 1994
Floyd Staggs(1).................................. 500 May 1994
Warren Montaldo(1)............................... 8,000 January 1996
4,000 May 1994
James Whelan (1)................................. 11,250 January 1996
Tuck Trainor..................................... 23,000 September 1992
Glenn Vittor (2)................................. 31,500 September 1992
Mark J. Mallis................................... 28,125 September 1992
Thomas Kaufman................................... 28,125 September 1992
Irmgard Kaufhold................................. 13,514 September 1992
Paul Bender...................................... 14,062 September 1992
Marc and Cindy Goldfarb.......................... 14,062 September 1992
John Lansing..................................... 11,812 September 1992
Gary Nadelman IRA................................ 56,250 September 1992
Seymour Nadelman................................. 42,187 September 1992
Syndie Nadleman.................................. 84,375 September 1992
Eugene Sorosky................................... 14,062 September 1992
Jill H. Swid..................................... 7,925 September 1992
Robin Swid....................................... 7,925 September 1992
Scott L. Swid.................................... 7,925 September 1992
Stephen C. Swid.................................. 15,870 September 1992
Glenn A. Bergenfield (3)......................... 12,500 N/A -- Option
- ---------------
(1) Formerly employed by USAT or a subsidiary of USAT.
(2) Received as underwriting compensation.
(3) A former director of USAT.
PLAN OF DISTRIBUTION
The holders of 3,665,174 shares of the USAT Common Stock, all of which
shares are currently outstanding, have advised USAT that they may, from time to
time, offer these shares pursuant to the Prospectus as Selling Stockholders at
the prices then prevailing on the American Stock Exchange or in isolated
transactions, at negotiated prices, with institutional or other investors and
that they have engaged no underwriter to act for them, although sales may be
effected for each of such holders through his, her or its personal
broker-dealer.
In addition, the holders of the Warrants (other than the December 17
Warrants) and the Options have advised USAT that, when and if they exercise
their respective securities, they may, from time to time, sell the underlying
shares of the USAT Common Stock in the manner described in the preceding
paragraph. Because the 2,000,000 shares of the USAT Common Stock underlying the
December 17 Warrants have been registered under the Securities Act pursuant to
this Registration Statement and none of the holders of the December 17 Warrants
is an affiliate of USAT as such term is defined in Rule 405 under the Securities
Act, such holders will not, in the opinion of Gold & Wachtel, LLP, general
counsel to USAT, require, after exercise of a December 17 Warrant in order to
resell, a prospectus (a) naming him, her or it as a Selling Stockholder with
respect to the shares of the USAT Common Stock issuable upon the exercise of the
December 17 Warrants and (b) otherwise complying with Section 10(a)(3) of the
Securities Act.
20
21
USAT, its officers, directors, affiliates and the Selling Stockholders are
obligated to take such steps as may be necessary to ensure that the offer and
sale by such parties of the 9,757,775 shares of the USAT Common Stock offered by
this Prospectus (the "Distribution") shall comply with the requirements of the
federal securities laws, including Rule 10b-6 (the "Rule") and other applicable
anti-manipulation provisions of the Exchange Act.
In general, Rule 10b-6 under the Exchange Act prohibits any person
connected with the Distribution from directly or indirectly bidding for, or
purchasing for any account in which he, she or it has a beneficial interest, any
shares of the USAT Common Stock or any right to purchase shares of the USAT
Common Stock, or attempting to induce any person to purchase shares of the USAT
Common Stock or rights to purchase shares of the USAT Common Stock, until after
he, she or it has completed his, her or its participation in the Distribution.
USAT has obtained joint and several agreements from its directors, officers
and affiliates not to purchase any shares of the USAT Common Stock or other
securities of the Company convertible into shares of the USAT Common Stock
during the Distribution Period in violation of the Rules and Regulations
promulgated under the Exchange Act, including, but not limited to, Rule 10(b)-6.
These affiliated securityholders are jointly and severally subject to a
nine-business day waiting ("cooling-off") period prior to their commencement of
offers or sales of their securities. They cannot make any bids or purchases
during this period and while the distribution herein continues. This Rule is
equally applicable to non-affiliated Selling Stockholders engaged in the
Distribution as well as the other Rule 10b-6 restrictions applicable to the
Selling Stockholders.
Because the Selling Stockholders will be subject to the anti-manipulation
provisions of Rule 10b-6, USAT will send written notice to all of them by
certified mail at least two business days prior to the effective date of this
Prospectus explaining their obligations under the Rule which begins two days
prior to the commencement of any distribution and continuing throughout the
period until their offers and sales terminate.
Unless granted an exemption by the Commission from Rule 10b-6, any
soliciting broker-dealers will be prohibited from engaging in any market making
activities in USAT's securities for the period from two business days prior to
any solicitation activity or the termination of any right that the underwriter
and soliciting broker-dealers may have to receive a fee for the exercise of
warrants following such solicitation. As a result, soliciting broker-dealers may
be unable to continue to provide a market for USAT's securities during certain
periods while the warrants are exercisable.
USAT is bearing all costs relating to the registration of the shares of the
USAT Common Stock offered by this Prospectus (other than fees and expenses, if
any, of counsel or other advisers to the Selling Stockholders). Any commissions,
discounts or other fees payable to broker-dealers in connection with any sale of
the USAT Common Stock will be borne by the Selling Stockholder selling such
shares.
LEGAL MATTERS
The validity of the securities offered hereby will be passed upon for the
Company by Gold & Wachtel, LLP, New York, New York.
MATERIAL CHANGES
On July 3, 1996 Gary S. Wolff resigned from his positions as Chief
Financial Officer, Chief Accounting Officer and Treasurer of USAT and as a
director, Chief Financial Officer and Treasurer of Good Ideas and U.S. Drug.
Effective that date, Joseph Bradley was elected Treasurer of USAT, Good Ideas
and U.S. Drug and simultaneously designated as their Acting Chief Financial
Officer and Acting Chief Accounting Officer.
As of March 31, 1996, there were notes payable by USAT to U.S. Drug in the
amount of $282,295 which, as extended, were due June 30, 1996. The indebtedness
was repaid and USAT has authorized a loan of $500,000 to U.S. Drug which amount
will be due December 31, 1996.
21
22
USAT has called the Annual Meeting of Stockholders for October 22, 1996 at
which time stockholders will be asked to elect two Class A Directors, to ratify
the appointment of Ernst & Young LLP as auditors for fiscal 1997 and to approve
a change of name of USAT to "Substance Abuse Technologies, Inc." The USAT Board
intends, if the U.S. Drug Merger and the Good Ideas Merger are consummated, to
merge all operating subsidiaries into USAT and operate as five operating
divisions: one conducting alcohol testing operations (currently conduced by
USAT), the second conducting drug testing operations (the intended operations of
U.S. Drug), the third offering laboratory testing for alcohol and drugs
(currently conducted by USAT's Biochemical Toxicology Laboratories ("Biotox")
division), the fourth offering human resource provider operations (currently
conducted by ProActive) and the fifth offering substance abuse programs
(currently offered by RSA). There can be no assurance that either or both of the
Mergers will be consummated or the reorganization otherwise effected.
COMMISSION POSITION ON INDEMNIFICATION
The USAT Board of Directors has authorized indemnification of directors and
officers of USAT to the fullest extent permitted by Delaware law.
Section 145(a) of the GCL permits a corporation to indemnify any person who
was or is a party or is threatened to be made a party to any threatened, pending
or completed action, suit or proceeding, whether civil, criminal, administrative
or investigative (other than an action by or in the right of the corporation),
by reason of the fact that he or she is or was a director, officer, employee or
agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation, partnership,
joint venture, trust or other enterprise against expenses (including attorneys'
fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred in connection with such action, suit or proceeding if he or she acted
in good faith and in a manner he or she reasonably believed to be in, or not
opposed to, the best interests of the corporation, and, with respect to any
criminal action or proceeding, had no reasonable cause to believe his or her
conduct was unlawful.
Under Section 145(b) of the GCL, a corporation also may indemnify any
person who was or is a party or is threatened to be made a party to any
threatened, pending or completed action or suit by or in the right of the
corporation to procure a judgment in its favor by reason of the fact that he or
she is or was a director, officer, employee or agent of the corporation, or is
or was serving at the request of the corporation as a director, officer,
employee or agent of another corporation, partnership, joint venture, trust or
other enterprise against expenses (including attorneys' fees) actually and
reasonably incurred by him or her in connection with the defense or settlement
of such action or suit if he or she acted in good faith and in a manner he or
she reasonably believed to be in, or not opposed to the best interests of the
corporation. However, in such an action by or on behalf of a corporation, no
indemnification may be in respect of any claim, issue or matter as to which the
person is adjudged liable to the corporation unless and only to the extent that
the court determines that, despite the adjudication of liability but in view of
all the circumstances, the person is fairly and reasonably entitled to indemnity
for such expenses which the court shall deem proper.
In addition, under Section 145(f) of the GCL, the indemnification provided
by Section 145 shall not be deemed exclusive of any other rights to which those
seeking indemnification may be entitled under any by-law, agreement, vote of
stockholders or disinterested directors or otherwise, both as to action in his
or her official capacity and as to action in another capacity while holding such
office.
Insofar as indemnification for liabilities arising under the Securities Act
may be permitted to directors, officers and controlling persons of USAT pursuant
to the foregoing provisions, or otherwise, USAT has been advised that in the
opinion of the Commission such indemnification is against public policy as
expressed in the Securities Act and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other than the
payment by USAT of expenses incurred or paid by a director, officer or
controlling person of USAT in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, USAT will, unless in the
opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Securities
Act and will be governed by the final adjudication of such issue.
22
23
- ------------------------------------------------------------
- ------------------------------------------------------------
NO DEALER, SALESPERSON OR OTHER PERSON HAS BEEN AUTHORIZED TO GIVE ANY
INFORMATION OR TO MAKE ANY REPRESENTATIONS IN CONNECTION WITH THIS OFFERING
OTHER THAN THOSE CONTAINED IN THIS PROSPECTUS AND, IF GIVEN OR MADE, SUCH
INFORMATION OR REPRESENTATIONS MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED
BY THE COMPANY.THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR A
SOLICITATION OF AN OFFER TO BUY THE SECURITIES OFFERED HEREBY TO ANY PERSON IN
ANY STATE OR OTHER JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION WOULD BE
UNLAWFUL. NEITHER THE DELIVERY OF THIS PROSPECTUS NOR ANY SALE MADE HEREUNDER
SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THE INFORMATION
CONTAINED HEREIN IS CORRECT AS OF ANY TIME SUBSEQUENT TO THE DATE HEREOF.
------------------------
TABLE OF CONTENTS
PAGE
----
Available Information...................... 2
Incorporation of Certain Information By
Reference................................ 3
The Company................................ 4
Risk Factors............................... 6
Dilution................................... 10
Use of Proceeds............................ 11
Selling Stockholders....................... 11
Plan of Distribution....................... 20
Legal Matters.............................. 21
Material Changes........................... 21
Commission Position on Indemnification..... 22
UNTIL NOVEMBER 13, 1996 (40 DAYS AFTER THE DATE OF THE PROSPECTUS), ALL
DEALERS EFFECTING TRANSACTIONS IN SECURITIES OFFERED HEREBY, WHETHER OR NOT
PARTICIPATING IN THIS DISTRIBUTION, MAY BE REQUIRED TO DELIVER A PROSPECTUS.
THIS DELIVERY REQUIREMENT IS IN ADDITION TO THE OBLIGATION OF DEALERS TO DELIVER
A PROSPECTUS WHEN ACTING AS UNDERWRITERS AND WITH RESPECT TO THEIR UNSOLD
ALLOTMENTS OR SUBSCRIPTIONS.
- ------------------------------------------------------------
- ------------------------------------------------------------
- ------------------------------------------------------------
- ------------------------------------------------------------
U.S. ALCOHOL TESTING
OF AMERICA, INC.
2,000,000 SHARES OF COMMON STOCK
($.01 PAR VALUE) ISSUABLE UPON EXERCISE
OF WARRANTS AND 9,757,775 SHARES
OFFERED BY SELLING STOCKHOLDERS
------------------------
PROSPECTUS
------------------------
October 4, 1996
- ------------------------------------------------------------
- ------------------------------------------------------------